It has been a boom time in the pharmaceutical sector, yesterday Tiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses.
Tiziana Life Sciences (LON:TILS) Develops Novel Investigational Treatment For Patients Infected with COVID-19
Utilizing Direct Delivery of Anti-Interlukin-6-Receptor Monoclonal Antibodies